DRTSW
Alpha Tau Medical Ltd.
Set alert
- YTD
- -6.33%
- 1 year
- -6.33%
- Open
- 0.3251
- Prev close
- 3.16
- Mkt cap
- 1.19B
- Vol
- 2.09K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 2.96
- High
- 3.05
- Forward P/E
- 0.00
- Beta
- 1.22
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 24, 2026
- 50-d avg
- 0.00
- 200-d avg
- 0.00
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.27
- EPS (TTM)
- 0.00
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -20.26M
- Total cash
- 100.64M
- Total debt
- 15.15M
- Return on equity
- -141.68%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
Consensus: none
Next earnings
Nov 24, 2026
Expected Nov 24, 2026. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 24, 2026 | Sep 30, 2026 | -0.14672 | — | — | — |
| Aug 10, 2026 | Jun 30, 2026 | -0.14088 | -0.50 | -0.36 | -254.91% |
| May 18, 2026 | Mar 31, 2026 | -0.12356 | -0.26 | -0.14 | -110.42% |
| Mar 9, 2026 | Dec 31, 2025 | -0.12101 | -0.14 | -0.02 | -15.69% |
| Nov 20, 2025 | Sep 30, 2025 | -0.11125 | -0.14922 | -0.04 | -34.13% |
| Aug 11, 2025 | Jun 30, 2025 | -0.1108 | -0.13 | -0.02 | -17.33% |
About Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer. The company is headquartered in Jerusalem, Israel.
- Country
- Israel
- Website
- alphatau.com
News
Your note
Sign in to keep a note on DRTSW — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| LMR Partners LLP | 6.38% | 1,494,631 | 4.47M | Jun 29, 2026 |
| Aristeia Capital, LLC | 2.57% | 602,350 | 1.80M | Jun 29, 2026 |
| MMCAP International, Inc. SPC | 1.91% | 447,622 | 1.34M | Jun 29, 2026 |
| Wolverine Asset Management, LLC | 1.37% | 319,910 | 956.53K | Jun 29, 2026 |
| Moore Capital Management, LP | 0.64% | 150,000 | 448.50K | Jun 29, 2026 |
| Tenor Capital Management Co., L.p. | 0.64% | 150,000 | 448.50K | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Collaborative Inv Ser Tr-SPAC and New Issue ETF | 0.05% | 12,221 | 36.54K | Dec 30, 2023 |